VRCA
Verrica Pharmaceuticals Inc.Company with tickers: VRCA
CIK
1660334
CUSIP
92511W207
Shares Outstanding
17,178,786
Website
https://www.verrica.com
Investor Relations
https://verrica.com/investor-connection/
13F Activity (30d)
2 filings
1 filers
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Lawrence Eichenfield | director | Appointed | 2026-06-09 |
| Paul B. Manning | director | Appointed | 2026-06-09 |